BPC-157 for Inflammation: Long-Term Follow-Up Findings Women Need to Know

What BPC-157 Actually Is, and Why the "Off-Label" Label Matters

BPC-157 is a synthetic 15-amino-acid peptide derived from a sequence found in human gastric juice. Researchers first isolated it in the 1990s and published early animal healing data through the laboratory of Predrag Sikiric at the University of Zagreb. It has never completed a Phase III clinical trial, and no regulatory agency has approved it for any human indication.

That makes every human use of BPC-157, including use for inflammation, strictly off-label. Off-label use is legal in many countries when prescribed by a clinician, but it means the dose, the duration, and the long-term risk profile have not been validated through the standard drug-approval process. For women, this gap is especially wide because reproductive-age women, pregnant people, and postmenopausal women are rarely represented even in the animal studies that exist.

How the peptide is thought to work

BPC-157 appears to modulate nitric oxide signaling and to interact with the vascular endothelial growth factor (VEGF) pathway, promoting angiogenesis and tissue repair at sites of injury. In rodent models, it has shown effects on the gut-brain axis, specifically on the vagus nerve, which connects gastrointestinal inflammation to systemic inflammatory signaling. A 2016 review in Current Neuropharmacology described BPC-157 as influencing dopaminergic and serotonergic systems in ways that may also reduce central sensitization to inflammatory pain.

It is sold online, dispensed by compounding pharmacies, and administered as a subcutaneous injection or oral capsule. None of these preparations have passed FDA manufacturing oversight for a human therapeutic indication.

The regulatory picture in 2025

The FDA placed BPC-157 on its list of bulk drug substances that may not be compounded under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. As of early 2024, the FDA's guidance lists BPC-157 among substances where the agency has determined that use in compounding raises safety concerns due to inadequate clinical evidence. This does not mean BPC-157 is seized at borders, but it does mean compounding pharmacies operating legally in the U.S. Should not be dispensing it. Women purchasing it from online peptide suppliers are buying an unregulated research chemical.

What Animal Studies Show About Inflammation (and Why Extrapolation Is Risky)

Most of the positive BPC-157 inflammation data comes from rats and mice. The body of work is genuinely impressive in scope, covering inflammatory bowel models, periodontitis, liver inflammation, tendon and ligament injury, and neuroinflammation. The limitation is equally genuine: rodent pharmacokinetics, immune profiles, and hormonal environments differ substantially from human physiology, and they differ even more from the cycling, pregnant, or postmenopausal female human.

Gut and gastrointestinal inflammation models

Multiple rat studies, including a widely cited 2012 paper in PLOS ONE, showed that BPC-157 reduced mucosal inflammation in acetic-acid-induced colitis models and accelerated healing of ulcerative lesions. Doses in these studies were typically 10 mcg/kg administered intraperitoneally, a route and dose with no direct human equivalent.

Women with inflammatory bowel disease (IBD) carry a specific burden: approximately 25% of women with Crohn's disease experience disease flares correlated with the menstrual cycle, and IBD itself affects fertility and pregnancy outcomes. The rodent colitis findings have led many women with IBD to try BPC-157 as an adjunct, but no controlled human data support this, and no data address cycle-phase variation in response.

Tendon, muscle, and joint inflammation

BPC-157 has shown consistent pro-healing effects in rat models of Achilles tendon transection, rotator cuff injury, and knee ligament damage. A 2010 study in the Journal of Orthopaedic Research reported significantly faster functional recovery in BPC-157-treated rats compared with saline controls. Women are at two to eight times higher risk of ACL injury than men of similar athletic exposure, partly because of hormonal effects of estrogen on ligament laxity across the menstrual cycle. That sex-specific vulnerability makes tendon-focused peptide research relevant to women. The evidence still does not extend to human clinical trials.

Neuroinflammation

In rodent models of traumatic brain injury and spinal cord inflammation, BPC-157 reduced microglial activation markers. Research published in Brain and Behavior in 2015 suggested that systemic BPC-157 crossed the blood-brain barrier in rats and attenuated neuroinflammatory cascades after cortical lesioning. Whether this translates to conditions more common in women, including migraine with neuroinflammatory features or postpartum neurological changes, is entirely unknown.

Long-Term Follow-Up: What the Data Actually Say

This is the section most BPC-157 content glosses over. Long-term follow-up data in humans do not exist, because no Phase II or Phase III trial has been completed and published in a peer-reviewed journal with a follow-up arm.

The longest animal follow-up data come from chronic dosing studies in rats. Sikiric's group published a series of papers through the 2010s documenting BPC-157 administration across weeks to months without observed organ toxicity in rodent cohorts. A 2019 paper in Current Pharmaceutical Design summarized over two decades of Zagreb laboratory findings and did not report oncogenic, hepatotoxic, or renal toxic signals in rodents at therapeutic dose ranges.

To organize what is and is not known, WomanRx uses the following evidence-tier framework for off-label peptides in women's health, applied here to BPC-157 long-term inflammation data:

Tier 1 (Human RCT with women-stratified data): Not available for BPC-157. Tier 2 (Human observational or open-label data): One small Slovenian pilot in peptic ulcer patients (n = 12) is sometimes cited but was never published in a peer-reviewed journal with accessible data. Tier 3 (Animal chronic-dosing studies): Available. Generally show no gross toxicity in rodents at doses approximating 10 mcg/kg over 30-to-90-day periods. Tier 4 (Mechanistic in vitro data): Available and extensive, supporting plausible anti-inflammatory mechanisms. Current evidence level for women specifically: Tier 4 only. Every claim about long-term safety or efficacy for women is extrapolated, not studied.

Why women's long-term data are especially thin

Clinical trials have historically enrolled fewer women, and when women are enrolled, cycle phase, hormonal contraceptive use, menopausal status, and prior pregnancy are rarely reported as covariates. A 2020 analysis in Biology of Sex Differences found that fewer than 30% of preclinical pharmacology studies reported animal sex, and when female animals were used, estrous cycle was reported in under 5% of papers. BPC-157 animal literature is no exception. This is not a reason to dismiss the animal data entirely, but it is a reason to be explicit: the long-term findings that circulate in wellness communities are rodent findings, and they are male-rodent-dominant findings.

BPC-157 Across Women's Life Stages

Reproductive years and cycle considerations

No published data examine BPC-157 pharmacokinetics across the menstrual cycle. Estrogen fluctuation affects nitric oxide synthase activity, which is one of BPC-157's proposed mechanistic targets. This means BPC-157's anti-inflammatory effect could theoretically vary across cycle phases, but this has not been tested in any published study.

Women using BPC-157 during reproductive years and trying to conceive should stop immediately, given the absence of reproductive safety data.

PCOS and metabolic inflammation

Polycystic ovary syndrome is partly an inflammatory condition. Women with PCOS show elevated C-reactive protein and interleukin-6 independent of obesity. BPC-157's proposed anti-inflammatory mechanisms are theoretically relevant, but no study has enrolled women with PCOS. Anyone with PCOS who is considering BPC-157 is doing so without any PCOS-specific evidence base.

Perimenopause and menopause

The menopausal transition is associated with a rise in systemic inflammation. Estradiol has direct anti-inflammatory effects on NF-kB signaling, and as estradiol falls during perimenopause, inflammatory markers tend to rise. Women sometimes seek peptides like BPC-157 as anti-inflammatory alternatives to or adjuncts to menopausal hormone therapy. No evidence supports this substitution, and menopausal hormone therapy has a substantially larger evidence base for managing menopausal symptoms and reducing inflammation-related risks. The Menopause Society (formerly NAMS) 2022 position statement does not mention BPC-157 and recommends against unproven supplements as replacements for evidence-based menopausal care.

Postpartum

Postpartum gut dysfunction, including postpartum IBD flares and increased intestinal permeability, is a documented phenomenon. Some women in postpartum online communities report using BPC-157 for gut healing. No postpartum safety data exist, and the lactation question is entirely unresolved (see below).

Endometriosis

Endometriosis is defined by chronic pelvic inflammation. Several researchers have proposed that peptides modulating VEGF and angiogenesis could theoretically affect endometrial lesion growth, a concern rather than a benefit, since endometriosis lesions depend on angiogenesis to survive. A 2021 review in Human Reproduction Update documented the central role of VEGF in endometriotic lesion vascularization. BPC-157's pro-angiogenic mechanism could theoretically worsen endometriosis. This is speculative in the absence of specific studies, but women with endometriosis should raise it explicitly with their clinician before considering BPC-157.

Pregnancy and Lactation Safety

Pregnancy: Do not use.

BPC-157 has no FDA pregnancy category because it has no FDA approval. Reproductive and developmental toxicology data are incomplete. No human pregnancy exposure data are published. Animal embryotoxicity studies have not been conducted and published to the standard required for drug approval. Given the peptide's effects on VEGF and angiogenesis, both of which are essential to normal placentation, there is no basis for assuming safety, and meaningful theoretical risk exists.

Any woman who becomes pregnant while using BPC-157 should discontinue immediately and inform her obstetric provider. Because BPC-157 is not a known teratogen with a defined washout requirement, no specific contraceptive mandate exists in the way it does for drugs like isotretinoin or methotrexate. The guidance is simpler: do not use BPC-157 if you are pregnant, trying to conceive, or not using reliable contraception, because risk cannot be quantified and the precautionary principle applies.

Lactation: Do not use.

Peptide transfer into breast milk is poorly studied for BPC-157 specifically. Larger peptides may be degraded in the neonatal gut, but smaller fragments could absorb. No lactation pharmacokinetic data exist for BPC-157. The NIH LactMed database does not contain an entry for BPC-157 as of mid-2025, which reflects the absence of data rather than a determination of safety. The conservative clinical recommendation is to avoid BPC-157 entirely while breastfeeding.

Contraception:

BPC-157 does not carry the same formal teratogen-risk-management designation as drugs in REMS programs. Women of reproductive age using BPC-157 are advised to use reliable contraception, not because a specific fetal malformation syndrome has been described, but because no safety data permit any reassurance.

Who This May Be Appropriate For, and Who Should Not Use It

This is an off-label, experimental compound. The following framing is not a recommendation; it is a structured summary of what the evidence does and does not support.

Women for whom BPC-157 may carry a lower relative risk of harm

• Postmenopausal women with no active cancer history, who have exhausted evidence-based anti-inflammatory options, and who are under close clinical monitoring
• Women with refractory gut conditions who have been counseled about the absence of human trial data and who are enrolled in a structured follow-up protocol with a physician

Even in these groups, the word "appropriate" is a stretch given the evidence tier. The more precise statement is: the known risk may be more acceptable in these groups than in others.

Women who should avoid BPC-157

• Pregnant women (theoretical vascular risk, no safety data)
• Women breastfeeding (no lactation data)
• Women trying to conceive
• Women with a current or prior hormone-sensitive cancer (BPC-157 is pro-angiogenic, a property that is relevant to tumor vascularization)
• Women with endometriosis (theoretical VEGF-mediated lesion growth concern)
• Women with uterine fibroids (fibroids are also vascularized tumors; pro-angiogenic effects are a theoretical concern)
• Women who have not had a baseline inflammatory panel, liver function tests, and kidney function measured, since there is no way to monitor for harm without a baseline

Reported Side Effects and What to Watch For

Because BPC-157 is unregulated and users self-report rather than entering clinical monitoring, the side-effect profile comes primarily from online communities and a small number of case reports rather than from pharmacovigilance databases.

Self-reported effects include nausea (particularly with oral preparations), injection-site reactions, and, in a minority of users, reports of heightened anxiety or mood changes. The anxiety signal is biologically plausible given BPC-157's reported interactions with dopamine and serotonin pathways, as described in a 2016 pharmacology review.

For women specifically, any effect on serotonin or dopamine signaling carries relevance across the menstrual cycle, since these neurotransmitters shift with estrogen and progesterone. A woman with premenstrual dysphoric disorder (PMDD) or a history of postpartum depression may be more sensitive to peptides affecting monoamine tone. This has not been studied.

No confirmed cases of serious organ toxicity have been published in the peer-reviewed literature for BPC-157 in humans, but the absence of published harm reports in an unregulated, unreported-use context is not the same as demonstrated safety.

What to Ask Your Clinician Before Considering BPC-157

If you are evaluating BPC-157 for inflammation, these are the specific questions worth raising with a women's-health provider:

• Is there an evidence-based anti-inflammatory treatment for my specific condition that I have not yet tried? Evidence-based options such as low-dose naltrexone for autoimmune inflammation, omega-3 supplementation for systemic inflammation, or menopausal hormone therapy for perimenopause-related inflammatory rise should be exhausted before considering an unregulated peptide.
• Can you order baseline labs before I start? At minimum: CRP, IL-6, liver function panel, creatinine, and CBC.
• How will we know if it is working or causing harm? Without a monitoring protocol, you are flying blind.
• What is the source of the BPC-157 you are recommending? Is the compounding pharmacy 503B-accredited and subject to FDA oversight? Given the 2024 FDA guidance, this question may be moot for U.S.-based compounders.

The Evidence Gap Is the Most Important Finding

Women have been historically underrepresented in clinical research. A 2021 NIH analysis found that women represented 47% of NIH-funded trial participants overall but remained severely underrepresented in pharmacokinetic substudies and in studies of novel or off-label compounds. For BPC-157, the gap is not 47% versus 53%. The gap is zero published human trials, period.

The enthusiasm for BPC-157 in wellness communities is understandable. Chronic inflammation disproportionately affects women, conditions like PCOS, endometriosis, autoimmune thyroiditis, and perimenopausal systemic inflammation leave many women inadequately served by standard-of-care options, and the animal data for BPC-157 are genuinely interesting. But the distance between "interesting rodent data" and "safe and effective for women" is the entire span of clinical development, and BPC-157 has not traveled it.

If you are considering BPC-157, the single most protective step you can take is to work with a clinician who will document your baseline, monitor your response, and report adverse events. Until trials are completed and published, every woman using BPC-157 is, in effect, a participant in an uncontrolled experiment. Framing it that way, with a baseline inflammatory panel and structured follow-up, at least makes the experiment informative.